Table_1_Hypomethylation of 111 Probes Predicts Poor Prognosis for Glioblastoma.XLSX (72.76 kB)

Table_1_Hypomethylation of 111 Probes Predicts Poor Prognosis for Glioblastoma.XLSX

Download (72.76 kB)
dataset
posted on 25.10.2019 by Qi Chen, Min Zhao, Chengliang Yin, Shiyu Feng, Jian Hu, Qiang Zhang, Xiaodong Ma, Wanguo Xue, Jinlong Shi

Glioblastoma (GBM) is a complicated brain tumor with heterogeneous outcome. Identification of effective biomarkers is an urgent need for the treatment decision-making and precise evaluation of prognosis. Based on a relatively large dataset of genome-wide methylation (138 glioblastoma patients), a joint-score of 111 methyl-probes was found to be of statistical significance for prognostic evaluation. Low joint-score were significantly associated with adverse outcomes (OS: P < 0.001, PFS: P = 0.03). Multivariable analyses adjusted for known risk factors confirmed the low joint-score of 111 methyl-probes as a high risk factor. The prognostic value of the methylated joint-score was further validated in another dataset of glioblastoma patients (OS: P = 0.006). Additionally, variance analysis revealed that aberrant genetic and epigenetic alterations were significantly associated with the joint-score of those methyl-probes. In conclusion, our results supported the joint-score of 111 methyl-probes as a potential prognosticator for the precision treatment of glioblastoma.

History

Licence

Exports